trastuzumabtislelizumaboxaliplatinpaclitaxelS-1SOXoesophagogastric junction cancergastric cancerThe First Affiliated Hospital of Nanjing Medical UniversityClinicalTrials.gov+2 more
…by body surface area). HER2-positive patients will also receive trastuzumab. Primary endpoint: 1-year overall survival. Secondary endpoints…